409 Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks

nan

DOI: 10.1093/bjd/ljad162.030

---

• What is this paper about?

  This paper analyzes how well the medication upadacitinib works for treating moderate-to-severe atopic dermatitis in both teenagers and adults over a 52-week period. The study looked at different doses of the medication (15mg and 30mg) and compared their effectiveness and safety.

• How did the authors study this?

  The research combined data from three phase 3 clinical trials (Measure Up 1, Measure Up 2, and AD Up). Patients were randomly assigned to take either 15mg upadacitinib, 30mg upadacitinib, or a placebo pill once daily. Some patients also used topical corticosteroids alongside their pills. After 16 weeks, patients who were taking placebo were switched to either 15mg or 30mg upadacitinib.

• What populations did the authors study?

  The study included both adolescents (12-17 years old) and adults with moderate-to-severe atopic dermatitis. The adolescent group was further divided into two age groups: 12 to under 16 years, and 16 to under 18 years.

• What did the authors find?

  Both doses of upadacitinib showed significant improvement in skin symptoms and itching in adults and teenagers. The 30mg dose generally showed better results than the 15mg dose. After 52 weeks, 70-83% of patients had major improvement in their skin symptoms, and 31-47% achieved clear or almost clear skin. Quality of life improved for both teenagers and adults, and anxiety and depression symptoms decreased. The medication showed similar safety results in both age groups.

• What conclusions can we draw?

  The authors concluded that upadacitinib worked similarly well in both teenagers and adults over the 52-week period, with acceptable safety in both age groups. Both the 15mg and 30mg doses were effective, though the 30mg dose showed better results.